Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Uma Sinha

Showing results (31-40 of 74) with videos related to

Pageof 8
Sort By:
Bioorganic & Medicinal Chemistry Letters|March 18, 2003
Design, synthesis, and structure-activity relationships of substituted piperazinone-based transition state factor Xa inhibitorsTing Su, Hua Yang, Deborah Volkots, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 18, 2005
Synergistic induction of tissue factor by coagulation factor Xa and TNF: evidence for involvement of negative regulatory signaling cascadesAyala Hezi-Yamit, Paul W Wong, Nga Bien-Ly, et al.
Blood|July 1, 2004
Transcriptional activation of hTERT through the NF-kappaB pathway in HTLV-I-transformed cellsUma Sinha-Datta, Izumi Horikawa, Eriko Michishita, et al.
Blood|January 18, 2013
Heparin rescues factor V Leiden-associated placental failure independent of anticoagulation in a murine high-risk pregnancy modelJianzhong An, Magarya S Waitara, Michelle Bordas, et al.
Thrombosis and Haemostasis|January 10, 2009
A randomized evaluation of betrixaban, an oral factor Xa inhibitor, for prevention of thromboembolic events after total knee replacement (EXPERT)Alexander G G Turpie, Kenneth A Bauer, Bruce L Davidson, et al.
Blood|October 26, 2011
SYK inhibition and response prediction in diffuse large B-cell lymphomaShuhua Cheng, Greg Coffey, X Hannah Zhang, et al.
Bioorganic & Medicinal Chemistry Letters|March 20, 2009
Anthranilamide-based N,N-dialkylbenzamidines as potent and orally bioavailable factor Xa inhibitors: P4 SARPenglie Zhang, Liang Bao, Jingmei Fan, et al.
Blood|June 17, 2011
Suppression of HTLV-1 replication by Tax-mediated rerouting of the p13 viral protein to nuclear specklesVibeke Andresen, Cynthia A Pise-Masison, Uma Sinha-Datta, et al.
Journal of Clinical Pharmacology|July 14, 2016
PRT062607 Achieves Complete Inhibition of the Spleen Tyrosine Kinase at Tolerated Exposures Following Oral Dosing in Healthy VolunteersGreg Coffey, Aradhana Rani, Andreas Betz, et al.
Blood|November 20, 2010
PRT-060318, a novel Syk inhibitor, prevents heparin-induced thrombocytopenia and thrombosis in a transgenic mouse modelMichael P Reilly, Uma Sinha, Pierrette André, et al.
Pageof 8

Showing results (31-40 of 74) with videos related to

Sort By:
Pageof 8
Bioorganic & Medicinal Chemistry Letters|March 18, 2003
Design, synthesis, and structure-activity relationships of substituted piperazinone-based transition state factor Xa inhibitorsTing Su, Hua Yang, Deborah Volkots, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 18, 2005
Synergistic induction of tissue factor by coagulation factor Xa and TNF: evidence for involvement of negative regulatory signaling cascadesAyala Hezi-Yamit, Paul W Wong, Nga Bien-Ly, et al.
Blood|July 1, 2004
Transcriptional activation of hTERT through the NF-kappaB pathway in HTLV-I-transformed cellsUma Sinha-Datta, Izumi Horikawa, Eriko Michishita, et al.
Blood|January 18, 2013
Heparin rescues factor V Leiden-associated placental failure independent of anticoagulation in a murine high-risk pregnancy modelJianzhong An, Magarya S Waitara, Michelle Bordas, et al.
Thrombosis and Haemostasis|January 10, 2009
A randomized evaluation of betrixaban, an oral factor Xa inhibitor, for prevention of thromboembolic events after total knee replacement (EXPERT)Alexander G G Turpie, Kenneth A Bauer, Bruce L Davidson, et al.
Blood|October 26, 2011
SYK inhibition and response prediction in diffuse large B-cell lymphomaShuhua Cheng, Greg Coffey, X Hannah Zhang, et al.
Bioorganic & Medicinal Chemistry Letters|March 20, 2009
Anthranilamide-based N,N-dialkylbenzamidines as potent and orally bioavailable factor Xa inhibitors: P4 SARPenglie Zhang, Liang Bao, Jingmei Fan, et al.
Blood|June 17, 2011
Suppression of HTLV-1 replication by Tax-mediated rerouting of the p13 viral protein to nuclear specklesVibeke Andresen, Cynthia A Pise-Masison, Uma Sinha-Datta, et al.
Journal of Clinical Pharmacology|July 14, 2016
PRT062607 Achieves Complete Inhibition of the Spleen Tyrosine Kinase at Tolerated Exposures Following Oral Dosing in Healthy VolunteersGreg Coffey, Aradhana Rani, Andreas Betz, et al.
Blood|November 20, 2010
PRT-060318, a novel Syk inhibitor, prevents heparin-induced thrombocytopenia and thrombosis in a transgenic mouse modelMichael P Reilly, Uma Sinha, Pierrette André, et al.
Pageof 8